What is the prognosis for ovarian cancer?

Ovarian cancer prognosis varies significantly depending on several key factors, including the histologic type and grade of the tumor, the stage at diagnosis, the patient’s age and overall health, and the extent of surgical cytoreduction achieved during initial treatment. Overall, the five-year relative survival rate for all stages combined is approximately 49% in the United States, according to recent SEER data. However, this figure masks substantial variation: for women diagnosed with localized disease (Stage I), the five-year survival rate exceeds 93%; for regional spread (Stage II–III), it declines to about 75% and 31%, respectively; and for distant metastatic disease (Stage IV), it drops to roughly 31%. High-grade serous carcinoma—the most common and aggressive subtype—often presents at an advanced stage and tends to have a poorer prognosis compared with low-grade serous, mucinous, or borderline tumors, which typically follow a more indolent course. Optimal cytoreductive surgery—defined as leaving no residual tumor larger than 1 cm—and subsequent platinum-based chemotherapy remain the cornerstone of treatment and are strongly associated with improved progression-free and overall survival. Emerging biomarkers, such as BRCA1/2 germline mutations and homologous recombination deficiency status, also inform prognosis and guide targeted therapies like PARP inhibitors, which have demonstrated significant survival benefits in selected populations.